Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Nexobrid Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Gel (lyophilized pwd + gel vehicle)—2g, 5g
Manufacturer
Generic Availability
NO
Mechanism of Action
The mixture of proteolytic enzymes in Nexobrid dissolves burn wound eschar. The specific components responsible for this effect have not been identified.
Nexobrid Indications
Indications
Eschar removal in deep partial thickness (DPT) and/or full thickness (FT) thermal burns.
Limitations of Use
Not established for treating: chemical or electrical burns; burns on the face, perineum, genitalia; burns on the feet of patients with diabetes mellits or occlusive vascular disease; circumferential burns; burns in patients with significant cardiopulmonary disease, including inhalation injury. Not for wounds contaminated with radioactive and other hazardous substances.
Nexobrid Dosage and Administration
Adult
Must be administrated by healthcare provider. Prepare and mix lyophilized pwd in gel vehicle prior to administration. Apply 3mm thick layer to an area up to 15% body surface area (BSA) in one session; leave in place for 4hrs. If area is >15% BSA, apply in 2 sessions separated by 24hrs. Total treatment area: max 20% BSA (40g of pwd) across 2 sessions. Wound treatment area preparation, pain management, application, product removal, others: see full labeling.
Children
Not established.
Nexobrid Contraindications
Contraindications
Hypersensitivity to bromelain, pineapples, papayas, papain.
Nexobrid Boxed Warnings
Not Applicable
Nexobrid Warnings/Precautions
Warnings/Precautions
Monitor for serious hypersensitivity reactions; remove Nexobrid and treat if occurs. Avoid exposure when preparing and handling product. Not for treatment of burn wounds where medical devices or vital structures could be exposed. Protect open wounds (eg, laceration, abraded skin, escharotomy incision) with protectant ointments or gauze. Avoid in uncontrolled coagulation disorders. Patients taking anticoagulants, on drugs affecting coagulation, low platelet counts, increased risk of bleeding (eg, peptic ulcers, sepsis): monitor for coagulation abnormalities and bleeding. Elderly. Pregnancy. Nursing mothers.
Nexobrid Pharmacokinetics
Elimination
Half-life: 12 ± 4.4 hours.
Nexobrid Interactions
Not Applicable
Nexobrid Adverse Reactions
Adverse Reactions
Pruritus, pyrexia; hypersensitivity reactions.
Nexobrid Clinical Trials
See Literature
Nexobrid Note
Not Applicable
Nexobrid Patient Counseling
See Literature
